Evidence map›Paper›PMID 33363564›Full record

ReviewFrontiers in genetics2020

How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

Beatriz Carvalho Henriques, Esther H Yang, Diego Lapetina, Michael S Carr, Vasyl Yavorskyy, Joshua Hague, Katherine J Aitchison

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Influence ofCanadian journal of psychiatry. Revue canadienne de psychiatrie · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. The pharmacogenetics ofFrontiers in pharmacology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Beatriz Carvalho HenriquesDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Esther H YangDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Diego LapetinaDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Michael S CarrDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Vasyl YavorskyyDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Joshua HagueDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Katherine J AitchisonDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many genetic variants in drug metabolizing enzymes and transporters have been shown to be relevant for treating psychiatric disorders. Associations are strong enough to feature on drug labels and for prescribing guidelines based on such data. A range of commercial tests are available; however, there is variability in included genetic variants, methodology, and interpretation. We herein provide relevant background for understanding clinical associations with specific variants, other factors that are relevant to consider when interpreting such data (such as age, gender, drug-drug interactions), and summarize the data relevant to clinical utility of pharmacogenetic testing in psychiatry and the available prescribing guidelines. We also highlight areas for future research focus in this field.

Indexed as

cytochrome P450 enzymesdrug metabolismdrug transporterspharmacogenomics (PGx)psychotropic drugs

Identifiers

PMID33363564
PMCPMC7753050

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.